Sequence and diversity of MHC DQA and DQB genes of the owl monkey Aotus nancymaae
Sequence and diversity of MHC DQA and DQB genes of the owl monkey Aotus nancymaae
复制标题
DOI：
10.1007/s002510000189
复制
发表时间：
2000-06-01
期刊：
影响因子：
3.2
通讯作者：
Daubenberger, CA
中科院分区：
文献类型：
--
作者：
Diaz, D;Naegeli, M;Daubenberger, CA
世界卫生组织（世卫组织）建议新世界灵长类动物南毛猴作为评估候选疟疾疫苗的模型，因为它对人类疟疾寄生虫恶性疟原虫和间日疟原虫的实验感染很敏感。我们在这里展示了MHC-DQA1的完整cDNA和MHC-DQB1/DQB2的多态性外显子2片段的核苷酸序列。在野外捕获的3只无亲缘关系的动物中，鉴定出5个MHC-DQA1等位基因。它们都属于一个谱系，即Aona-DQA1*27。这一谱系尚未在任何其他研究过的新大陆猴子物种中被描述。在一组19只无亲缘关系的动物中，鉴定出14个Aona-DQB1等位基因，并将其分为Aona-DQB1*22和Aona-DQB1*23两个谱系。这些谱系以前在普通狨猴和棉顶绢毛猴中被描述过。此外，还鉴定出两个与HLA-DQB2序列高度相似的Aona-DQB2序列。MHC DQ肽结合口袋1和4的必需氨基酸残基在HLA-DQ和Aona-DQ分子之间是保守或半保守的，表明它们有能力结合类似的肽库。这些结果充分支持使用猕猴作为评估未来亚单位候选疫苗的动物模型。
The New World primate Aotus nancymaae has been recommended by the World Health Organization (WHO) as a model for evaluation of malaria vaccine candidates, given its susceptibility to experimental infection with the human malaria parasites Plasmodium falciparum and Plasmodium vivax. We present here the nucleotide sequences of the complete cDNA of MHC-DQA1 and of the polymorphic exon 2 segments of MHC-DQB1/DQB2. In a group of three nonrelated animals captured in the wild, five alleles of MHC-DQA1 could be identified. They all belong to one lineage, namely Aona-DQA1*27. This lineage has not been described in any other New World monkey species studied. In a group of 19 unrelated animals, 14 Aona-DQB1 alleles could be identified which are grouped into the two lineages Aona-DQB1*22 and Aona-DQB1*23. These lineages have been described previously in the common marmoset and cotton-top tamarin. In addition, two Aona-DQB2 sequences could be identified which are highly similar to HLA-DQB2 sequences. Essential amino acid residues contributing to MHC DQ peptide binding pockets number 1 and 4 are conserved or semi-conserved between HLA-DQ and Aona-DQ molecules, indicating a capacity to bind similar peptide repertoires. These results fully support the use of Aotus monkeys as an animal model for evaluation of future subunit vaccine candidates.